| 29.12 1.87 (6.86%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 54.04 |
1-year : | 80.59 |
| Resists | First : | 46.27 |
Second : | 69 |
| Pivot price | 29.28  |
|||
| Supports | First : | 9.5 |
Second : | 7.9 |
| MAs | MA(5) : | 31.51 |
MA(20) : | 32.75 |
| MA(100) : | 11.55 |
MA(250) : | 8.25 |
|
| MACD | MACD : | 2.8 |
Signal : | 3.9 |
| %K %D | K(14,3) : | 39.8 |
D(3) : | 40.2 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 69 | Low : | 3.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RGC ] has closed above bottom band by 48.7%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.51 - 29.69 | 29.69 - 29.86 |
| Low: | 26.65 - 26.85 | 26.85 - 27.04 |
| Close: | 28.8 - 29.11 | 29.11 - 29.4 |
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Fri, 21 Mar 2025
Why Regencell Bioscience Holdings Ltd. (RGC) Surged On Thursday? - Yahoo Finance
Thu, 20 Mar 2025
10 Micro-, Small-Cap Firms Dominate Thursday’s Gains - Insider Monkey
Thu, 20 Mar 2025
Regencell stock soars to 52-week high, hits $45 amid staggering growth - Investing.com
Tue, 18 Mar 2025
Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews
Mon, 17 Mar 2025
Why Regencell Bioscience Holdings Limited (RGC) Soared Last Week? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 13 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 93.8 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 297 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.2 % |
| Return on Equity (ttm) | -43.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -88.25 |
| PEG Ratio | 0 |
| Price to Book value | 46.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -94.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|